Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
Pascoe J, Jackson A, Gaskell C, Gaunt C, Thompson J, Billingham L, Steven N · BMC cancer
Background : Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of β-hydroxy-β-methylbutyrate, arginine, and glutamine (HMB/Arg/Gln) was assessed in newly diagnosed patients. Methods : NOURISH, a prospective, two-arm, open-label, multi-centre, randomised…